Somatropin (HGH)
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Somatropin is recombinant human growth hormone (rHGH) — growth hormone manufactured via recombinant DNA technology, chemically identical to the GH your pituitary makes. It is the direct hormone, not a secretagogue. Where Sermorelin, CJC-1295, Ipamorelin, and Tesamorelin coax your own pituitary into releasing more GH on its own pulsatile schedule, somatropin bypasses the pituitary entirely and floods the system with GH directly. It’s sold under multiple brand names — Genotropin, Humatrope, Norditropin, Zorbtive — and is prescription-only.
That distinction — make your own vs. inject the finished hormone — is the central frame for understanding somatropin. It’s not a value judgment; both are real tools. But it changes the physiology, the regulatory status, the safety surface, and which product an honest reader is pointed toward.
What does it do in my body?
Somatropin binds GH receptors throughout the body and produces effects through two channels:
- Indirectly — it drives the liver to produce IGF-1, the downstream mediator of most of GH’s growth, repair, and anabolic effects. This is the same IGF-1 elevation the secretagogues achieve, just reached by a different route.
- Directly — GH receptors on fat and other tissues mediate lipolysis (fat breakdown) and other metabolic effects independent of IGF-1.
The key physiological difference vs. secretagogues: somatropin is a non-pulsatile flood. Your natural GH is released in pulses, with somatostatin damping it when levels rise — a built-in feedback brake. Injected somatropin overrides that rhythm, holding GH elevated in a pattern your body never produces on its own. The secretagogues, by contrast, work through your pituitary, so the pulsatility and the somatostatin brake stay intact. That’s the mechanistic root of why supraphysiologic somatropin carries a heavier side-effect profile than the secretagogue path.
How can it help me?
- Where the science stands: **** — 30 studies cited, 17 human trials, Phase 3 reached
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
OHM grades somatropin Tier A / Safety Yellow. The yellow specifically captures the supraphysiologic-dose concern; at physiologic GHD-replacement dosing the profile is benign.
At supraphysiologic doses: insulin resistance, edema, carpal tunnel syndrome, joint pain. The two that matter most for honest content:
- Insulin resistance / glucose dysregulation — GH is counter-regulatory to insulin; chronic supraphysiologic GH pushes blood glucose up and can unmask or worsen insulin resistance. This is the routine monitoring concern (fasting glucose, HbA1c) in anyone using GH above replacement.
- Acromegaly-type effects with chronic excess — sustained supraphysiologic GH produces the soft-tissue and skeletal overgrowth pattern seen in acromegaly (the disease of GH excess): enlarged hands/feet/jaw, organ enlargement.
- Theoretical cancer-signaling concern with chronic supraphysiologic use — GH drives IGF-1, and elevated IGF-1 is the central oncology concern across the whole IGF-axis class (the prostate/breast/colorectal epidemiology covered in depth under IGF-1 DES). Standard clinical practice screens for and avoids active malignancy. This is information, not a scare line: at physiologic replacement levels the concern is far smaller than at the supraphysiologic doses used for body composition.
Contraindications: active cancer or cancer history (IGF-axis mitogenic concern), pregnancy/breastfeeding, uncontrolled diabetes.
Regulatory status: FDA-approved, multiple brands (Genotropin, Humatrope, Norditropin, Zorbtive, biosimilars), prescription-only. WADA-prohibited at all times. This is the one compound in the GH/IGF reference family with a full approval dossier behind it — not a research chemical, not RUO, an actual prescription pharmaceutical.
Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
Somatropin’s legitimate path is a prescription — it’s approved for GH deficiency (pediatric and adult), AIDS/HIV wasting, Turner syndrome, Prader-Willi syndrome, idiopathic short stature, and short bowel syndrome [0035; peptidelist]. Physiologic replacement dosing in a genuinely GH-deficient adult is a well-characterized clinical protocol with a benign safety profile (see below). The gray-market, non-prescription, supraphysiologic-dose use for body composition is where the risk profile changes — and where it stops being the FDA-approved use case.
Most people reaching for “more GH” do not need the exogenous hormone. They’re chasing the IGF-1 elevation and the recovery/body-composition benefits — and the GH-secretagogue peptides (CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, MK-677 (Ibutamoren)) deliver that elevation through the body’s own physiology, with the pulsatility and feedback brake intact, no prescription required, and a much lighter side-effect surface. See the gh-to-igf1-conversion guide for the full mechanism walkthrough of how secretagogues drive the same IGF-1 endpoint from the upstream side.
What should I avoid combining — and what's synergistic?
Somatropin (HGH) doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
How can I buy this?
We don't have a verified affiliate source for Somatropin (HGH) yet, so there's no coupon or vendor link here — we won't point you to a seller we haven't vetted. When buying any research-use-only peptide, the single biggest variable is the supply chain: insist on a vendor that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity. Working with a peptide-literate clinician is one solid route — see our provider directory — or check back as our verified sources list grows.
Somatropin is recombinant human growth hormone (rHGH) — the GH molecule itself, made in the lab, chemically identical to what your pituitary produces. Unlike almost everything else in this KB, it is an actual FDA-approved prescription drug with a real approval dossier behind it — a different regulatory footing than the research-chemical peptides covered elsewhere here, and this article is precise about that distinction throughout.
| Class | Recombinant human growth hormone (rHGH) — the GH molecule itself, produced via recombinant DNA technology, identical to pituitary GH |
| Mechanism (one line) | Binds GH receptors → drives liver IGF-1 production (indirect) + direct lipolytic/metabolic effects (direct); non-pulsatile, overrides the body’s own somatostatin brake |
| Evidence base | **** — 30 studies cited, 17 human trials, Phase 3 reached |
| Safety record | Tier A / Safety Yellow — benign at physiologic replacement dosing; supraphysiologic doses carry insulin resistance, edema, carpal tunnel, joint pain, and acromegaly-type overgrowth risk |
| Regulatory status | FDA-approved, prescription-only (Genotropin, Humatrope, Norditropin, Zorbtive, biosimilars); WADA-prohibited at all times |
What it is
Somatropin is recombinant human growth hormone (rHGH) — growth hormone manufactured via recombinant DNA technology, chemically identical to the GH your pituitary makes. It is the direct hormone, not a secretagogue. Where Sermorelin, CJC-1295, Ipamorelin, and Tesamorelin coax your own pituitary into releasing more GH on its own pulsatile schedule, somatropin bypasses the pituitary entirely and floods the system with GH directly. It’s sold under multiple brand names — Genotropin, Humatrope, Norditropin, Zorbtive — and is prescription-only.
That distinction — make your own vs. inject the finished hormone — is the central frame for understanding somatropin. It’s not a value judgment; both are real tools. But it changes the physiology, the regulatory status, the safety surface, and which product an honest reader is pointed toward.
How it works
Somatropin binds GH receptors throughout the body and produces effects through two channels:
- Indirectly — it drives the liver to produce IGF-1, the downstream mediator of most of GH’s growth, repair, and anabolic effects. This is the same IGF-1 elevation the secretagogues achieve, just reached by a different route.
- Directly — GH receptors on fat and other tissues mediate lipolysis (fat breakdown) and other metabolic effects independent of IGF-1.
The key physiological difference vs. secretagogues: somatropin is a non-pulsatile flood. Your natural GH is released in pulses, with somatostatin damping it when levels rise — a built-in feedback brake. Injected somatropin overrides that rhythm, holding GH elevated in a pattern your body never produces on its own. The secretagogues, by contrast, work through your pituitary, so the pulsatility and the somatostatin brake stay intact. That’s the mechanistic root of why supraphysiologic somatropin carries a heavier side-effect profile than the secretagogue path.
What the research shows
The evidence base here is genuinely strong — the strongest of any compound in this GH/IGF reference family by a wide margin. Per peptidelist, somatropin carries 30 studies cited, 17 human trials, Phase 3 reached.
The site’s evidence summary: “Thirty human studies, including 10 randomized controlled trials, demonstrate that somatropin is safe and effective for promoting height gain in growth hormone deficiency and other growth disorders,” with newer once-weekly formulations (somatrogon, lonapegsomatropin) showing noninferior-to-superior efficacy vs. daily dosing in children, and biosimilars matching reference products.
Named anchors (all — third-party-sourced citations pending the citation-verification pass):
- Biller BMK et al. 2025 J Clin Endocrinol Metab — foresiGHt Trial: once-weekly lonapegsomatropin reduced trunk fat and increased lean mass vs. placebo in adults with GH deficiency. 41420532
- Deal CL et al. 2022 J Clin Endocrinol Metab — weekly somatrogon noninferior to daily somatropin for height velocity in GHD children. 35405011
- Thornton PS et al. 2021 J Clin Endocrinol Metab — heiGHt Trial: weekly lonapegsomatropin superior to daily somatropin for height velocity. 34272849
- Keating GM, Wellington K 2004 Drugs — somatropin (Zorbtive) reduced parenteral-nutrition dependence in short bowel syndrome. 15200350
- Sleman N, Khalil A 2023 Ann Med Surg — somatropin reduced alveolar bone resorption and improved healing after tooth extraction. 37113816
On the muscle-growth claim specifically, peptidelist grades it strong (13 studies, 4 RCTs, n=483) — though note most of the human RCT base concerns GH-deficient populations (height gain, body composition in GHD adults), not healthy-adult performance enhancement. That’s the honest read: the approval-grade data is for deficiency states; off-label use in non-deficient adults rides on mechanism + the deficiency data, not on dedicated RCTs in that population.
Real-world protocol
The information here is educational only. Somatropin is an FDA-approved prescription drug; obtaining or using it without a prescription is illegal in the US. This is not medical advice.
Somatropin’s legitimate path is a prescription — it’s approved for GH deficiency (pediatric and adult), AIDS/HIV wasting, Turner syndrome, Prader-Willi syndrome, idiopathic short stature, and short bowel syndrome [0035; peptidelist]. Physiologic replacement dosing in a genuinely GH-deficient adult is a well-characterized clinical protocol with a benign safety profile (see below). The gray-market, non-prescription, supraphysiologic-dose use for body composition is where the risk profile changes — and where it stops being the FDA-approved use case.
Most people reaching for “more GH” do not need the exogenous hormone. They’re chasing the IGF-1 elevation and the recovery/body-composition benefits — and the GH-secretagogue peptides (CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, MK-677 (Ibutamoren)) deliver that elevation through the body’s own physiology, with the pulsatility and feedback brake intact, no prescription required, and a much lighter side-effect surface. See the gh-to-igf1-conversion guide for the full mechanism walkthrough of how secretagogues drive the same IGF-1 endpoint from the upstream side.
Side effects & management
OHM grades somatropin Tier A / Safety Yellow. The yellow specifically captures the supraphysiologic-dose concern; at physiologic GHD-replacement dosing the profile is benign.
At supraphysiologic doses: insulin resistance, edema, carpal tunnel syndrome, joint pain. The two that matter most for honest content:
- Insulin resistance / glucose dysregulation — GH is counter-regulatory to insulin; chronic supraphysiologic GH pushes blood glucose up and can unmask or worsen insulin resistance. This is the routine monitoring concern (fasting glucose, HbA1c) in anyone using GH above replacement.
- Acromegaly-type effects with chronic excess — sustained supraphysiologic GH produces the soft-tissue and skeletal overgrowth pattern seen in acromegaly (the disease of GH excess): enlarged hands/feet/jaw, organ enlargement.
- Theoretical cancer-signaling concern with chronic supraphysiologic use — GH drives IGF-1, and elevated IGF-1 is the central oncology concern across the whole IGF-axis class (the prostate/breast/colorectal epidemiology covered in depth under IGF-1 DES). Standard clinical practice screens for and avoids active malignancy. This is information, not a scare line: at physiologic replacement levels the concern is far smaller than at the supraphysiologic doses used for body composition.
Contraindications: active cancer or cancer history (IGF-axis mitogenic concern), pregnancy/breastfeeding, uncontrolled diabetes.
Regulatory status
FDA-approved, multiple brands (Genotropin, Humatrope, Norditropin, Zorbtive, biosimilars), prescription-only. WADA-prohibited at all times. This is the one compound in the GH/IGF reference family with a full approval dossier behind it — not a research chemical, not RUO, an actual prescription pharmaceutical.
Sources
- — thepeptidelist.com somatropin profile: FDA-approved status, brands, 30 studies / 17 human / Phase 3, named RCTs (all), mechanism, prescription availability.
- — grading: Somatropin Tier A/Yellow (lines 266–274); the supraphysiologic-dose + cancer-signaling safety framing.
- Named anchors (all): Biller 2025 41420532; Deal 2022 35405011; Thornton 2021 34272849; Keating & Wellington 2004 15200350; Sleman & Khalil 2023 37113816.
Content migrated from gh-igf-reference-cluster.md (2026-06-10 build) per the 2026-07-16 cluster-elimination directive — no facts added or removed from the source article’s somatropin section.
See also: IGF-1 DES, PEG-MGF, CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, MK-677 (Ibutamoren), CJC-1295 / Ipamorelin.
Sources & references
- — thepeptidelist.com somatropin profile: FDA-approved status, brands, 30 studies / 17 human / Phase 3, named RCTs (all), mechanism, prescription availability.
- — grading: Somatropin Tier A/Yellow (lines 266–274); the supraphysiologic-dose + cancer-signaling safety framing.
- Named anchors (all): Biller 2025 41420532; Deal 2022 35405011; Thornton 2021 34272849; Keating & Wellington 2004 15200350; Sleman & Khalil 2023 37113816.
Content migrated from gh-igf-reference-cluster.md (2026-06-10 build) per the 2026-07-16 cluster-elimination directive — no facts added or removed from the source article’s somatropin section.
See also: IGF-1 DES, PEG-MGF, CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, MK-677 (Ibutamoren), CJC-1295 / Ipamorelin.